Ildong 바카라사이트 벳무브 Group’s Yunovia presents GLP-1 novel drug candidate data at American Diabetes Association
Fewer gastrointestinal side effects, possibility of oral 바카라사이트 벳무브…Early clinical findings, including weight loss benefits, are to be unveiled at ADA
[by Sung, Jae Jun] Yunovia, a novel drug development subsidiary of Ildong 바카라사이트 벳무브 Group, announced on June 10 that it will disclose early clinical results of its metabolic disease treatment candidate, ‘ID110521156 (development code),’ at the American Diabetes Association (ADA) meeting scheduled to take place in Chicago, USA, from June 20 to 23 (local time).
ID110521156 is a small-molecule synthetic new drug 바카라사이트 벳무브 designed for oral administration. It belongs to the glucagon-like peptide 1 (GLP-1) receptor agonist (RA) class that promotes insulin secretion, regulates blood glucose levels, and suppresses appetite. According to the company, the 바카라사이트 벳무브’s differentiation lies in its high productivity and ease of administration, distinguishing it from existing peptide-based treatments, which rely on injections.
Yunovia is currently conducting a multiple ascending dose (MAD) study on the 바카라사이트 벳무브 compound, following the completion of a single ascending dose (SAD) study. At the upcoming ADA meeting, the company plans to present a summary of results and key data from the SAD and MAD studies in a poster format.
The company states that the SAD study indicated that ID110521156 tends to produce fewer gastrointestinal side effects than other 바카라사이트 벳무브 receptor agonists. In the MAD study, the compound demonstrated a weight loss effect at effective doses without the need for a separate titration process.
“From the early stages of clinical trials, Yunovia has actively collaborated with major overseas 바카라사이트 벳무브 companies, aligning its strategy with global trends,” an Ildong 바카라사이트 벳무브 Group official said. “We plan to aggressively pursue licensing-out (L/O) opportunities and the discovery of new partners moving forward.”